Skip to main content
. 2023 Aug 10;11(8):2247. doi: 10.3390/biomedicines11082247

Figure 2.

Figure 2

Figure 2

Figure 2

Figure 2

Figure 2

Figure 2

Figure 2

Figure 2

Figure 2

(A) Overlap propensity score weighted odds ratios of dates of any statin prescription for any type of brain tumor. (B) Overlap propensity score weighted odds ratios of dates of lipophilic statin prescription for any type of brain tumor. (C) Overlap propensity score weighted odds ratios of dates of hydrophilic statin prescription for any type of brain tumor. (D) Overlap propensity score weighted odds ratios of dates of any type of statin prescription for malignant brain tumors. (E) Overlap propensity score weighted odds ratios of dates of lipophilic statin prescription for malignant brain tumors. (F) Overlap propensity score weighted odds ratios of dates of hydrophilic statin prescription for malignant brain tumors. (G) Overlap propensity score weighted odds ratios of dates of any type of statin prescription for benign brain tumors. (H) Overlap propensity score weighted odds ratios of dates of lipophilic statin prescription for benign brain tumors. (I) Overlap propensity score weighted odds ratios of dates of hydrophilic statin prescription for benign brain tumors.